3 VAN DE GRAAFF DRIVE, BURLINGTON, MA
Fractyl Health, Inc. 2026 Annual Meeting Results and Director Elections
Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
Reports First Quarter 2026 Financial Results and Business Updates
Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes
Annual Report to Security Holders
Earnings Release
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
SEC Staff Correspondence
Correspondence